株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

女性不妊症治療薬の世界市場:2019年~2023年

Global Female Infertility Drugs Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 905960
出版日 ページ情報 英文 129 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
女性不妊症治療薬の世界市場:2019年~2023年 Global Female Infertility Drugs Market 2019-2023
出版日: 2019年08月01日 ページ情報: 英文 129 Pages
概要

世界の女性不妊症治療薬市場は、女性不妊症の高い有病率、女性不妊症の高リスク因子、および有害転帰と高額な非薬物療法などが市場成長促進要因となり、予測期間中に5%以上のCAGRで拡大する見込みです。ただし、代替治療オプションの利用可能性、質の評価が弱い後期パイプライン、および厳しい規制などが、予測期間中の女性不妊症治療薬産業の成長を妨げる可能性があります。

当レポートでは、世界の女性不妊症治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代用品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:RoA別

  • 市場セグメンテーション:RoA別
  • RoA別比較:市場規模および予測(2018年~2023年)
  • 非経口
  • 経口
  • その他
  • 市場機会:RoA別

第7章 顧客情勢

第8章 地域別景観

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 女性の不妊に関する意識の高まり
  • 患者支援プログラム
  • バイオシミラーの導入

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31566

About this market

Technavio's female infertility drugs market analysis considers sales from segments including parenteral, oral, and others. Our analysis also considers the sales of female infertility drugs in Asia, Europe, North America, and ROW. In 2018, the parenteral segment had a significant market share, and this trend is expected to continue over the forecast period. The parenteral route is more convenient for peptide drugs. This factor will play a significant role in the parenteral segment to maintain its market position. Also, our global female infertility drugs market report looks at factors such as the high prevalence of female infertility, high-risk factors for female infertility, and adverse outcomes and high cost of non-therapeutics. However, the availability of alternative treatment options, weak late-stage pipeline, and stringent regulations may hamper the growth of the female infertility drugs industry over the forecast period.

Overview

Adverse outcomes and high cost of non-therapeutics

Non-therapeutics such as ART procedures, ICSI, IUI, crypto preservation of gametes and embryos, and IVF are expensive. Also, the cost burden on patients in the US is high due to lack of insurance coverage. These factors will boost the demand for female infertility drugs and lead to the expansion of the global female infertility drugs market at a CAGR of over 5% during the forecast period.

Introduction of biosimilars

Biosimilars are identical copies of original biologics, which are highly expensive. This is driving the demand for biosimilars. In addition, they are gaining traction in the market because they promote patient adherence. This factor is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global female infertility drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global female infertility drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female infertility drugs manufacturers, that include Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, and Sanofi.

Also, the female infertility drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Oral - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing awareness about female infertility
  • Patient assistance programs
  • Introduction of biosimilars

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • Ferring BV
  • Merck KGaA
  • Novartis AG
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: RoA - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by RoA
  • Exhibit 19: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by RoA
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Number of STD cases in US 2017
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Prevalence of infertility in some Indian states
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Some of the health problems associated with the use of ART
  • Exhibit 46: Pipeline molecules for treatment of female infertility: Overview
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Cost comparison of follitropin alfa
  • Exhibit 49: Vendor landscape
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Vendors covered
  • Exhibit 52: Vendor classification
  • Exhibit 53: Market positioning of vendors
  • Exhibit 54: Allergan Plc - Vendor overview
  • Exhibit 55: Allergan Plc - Product segments
  • Exhibit 56: Allergan Plc - Organizational developments
  • Exhibit 57: Allergan Plc - Geographic focus
  • Exhibit 58: Allergan Plc - Segment focus
  • Exhibit 59: Allergan Plc - Key offerings
  • Exhibit 60: Allergan Plc - Key customers
  • Exhibit 61: Ferring BV - Vendor overview
  • Exhibit 62: Ferring BV - Product segments
  • Exhibit 63: Ferring BV - Organizational developments
  • Exhibit 64: Ferring BV - Key offerings
  • Exhibit 65: Ferring BV - Key customers
  • Exhibit 66: Merck KGaA - Vendor overview
  • Exhibit 67: Merck KGaA - Business segments
  • Exhibit 68: Merck KGaA - Organizational developments
  • Exhibit 69: Merck KGaA - Geographic focus
  • Exhibit 70: Merck KGaA - Segment focus
  • Exhibit 71: Merck KGaA - Key offerings
  • Exhibit 72: Merck KGaA - Key customers
  • Exhibit 73: Novartis AG - Vendor overview
  • Exhibit 74: Novartis AG - Business segments
  • Exhibit 75: Novartis AG - Organizational developments
  • Exhibit 76: Novartis AG - Geographic focus
  • Exhibit 77: Novartis AG - Segment focus
  • Exhibit 78: Novartis AG - Key offerings
  • Exhibit 79: Novartis AG - Key customers
  • Exhibit 80: Sanofi - Vendor overview
  • Exhibit 81: Sanofi - Business segments
  • Exhibit 82: Sanofi - Organizational developments
  • Exhibit 83: Sanofi - Geographic focus
  • Exhibit 84: Sanofi - Segment focus
  • Exhibit 85: Sanofi - Key offerings
  • Exhibit 86: Sanofi - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: Definition of market positioning of vendors
Back to Top